Ganitumab

Research use only, not for human use.

Ganitumab (AMG 479) is a highly potent monoclonal antibody targeting the type 1 insulin-like growth factor receptor (IGF1R). Recognized for binding IGF1R at low concentrations with a KD value of 0.22 nM, Ganitumab inhibits IGF1R interactions with IGF1 and IGF2 in mice, making it useful for cancer research.

Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer.

Western Blot Analysis Cell Line:CT26 cells Concentration:0.032-500 nM Incubation Time:10 minutes Result:Inhibited IGF1-induced autophosphorylation of mIGF1R in CT26 murine colon carcinoma cells in a dose-dependent manner.

Animal Model:Na?ve and tumor-bearing miceDosage:1 mg/doseAdministration:Intraperitoneal injectionResult:Inhibited the IGF1-induced activation of mIGF1R and inhibited 80% tumor growth.Animal Model:Male athymic nude mice Dosage:300 μg/dose Administration:Intraperitoneal injection, twice per week for a total of five doses Result:Had significantly higher serum glucose levels than hIgG1-pretreated mice.Increased serum levels of mIGF1, mIGFPB3 and mGH.Animal Model:Female athymic nude mice Dosage:300 μg/dose Administration:Intraperitoneal injection, twice per week for a total of five dosesResult:Reduced the number of peripheral neutrophils up to 50% compared with hIgG1 controls.

——

Angiogenesis

IGF-1R

IGF-1R

——

——

905703-97-1

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years